<DOC>
	<DOCNO>NCT00372710</DOCNO>
	<brief_summary>Zoledronic acid selectively bind bone protects metastasize tumor cell . This study evaluate safety efficacy zoledronic acid add standard therapy breast cancer patient metastatic bone lesion .</brief_summary>
	<brief_title>Safety/Efficacy Intravenous Zoledronic Acid When Added Standard Therapies Patients With Breast Cancer Metastatic Bone Lesions</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion criterion Confirmed diagnosis Breast Cancer least one breast cancerrelated bone lesion No treatment bisphosphonates within 6 month prior inclusion study Good health status ( ECOG Performance status 02 ) Exclusion criterion Patients least one breast cancerrelated bone lesion detectable conventional radiograph bone ( plain film ) screen Abnormal renal function History diseases influence bone metabolism Paget 's disease primary hyperparathyroidism Pregnancy lactation Current active dental problem include infection teeth jawbone ( maxilla mandibular ) ; dental fixture trauma , current prior diagnosis osteonecrosis jaw ( ONJ ) , expose bone mouth , slow healing dental procedure , recent ( within 6 week ) plan dental jaw surgery ( e.g..extraction , implant )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Palliation</keyword>
	<keyword>Bone metastasis</keyword>
	<keyword>Zoledronic acid</keyword>
</DOC>